• Oleanolic Acid Disrupts Hepatic FXR Signaling and Bile Acid

  2026-06-17

  This study uncovers how high-dose oleanolic acid (OA) disrupts hepatocyte tight junctions and impairs farnesoid X receptor (FXR)-mediated bile acid transport, leading to cholestatic liver injury. These findings clarify the molecular mechanisms underlying OA-induced hepatic toxicity and highlight the critical role of FXR signaling in liver barrier and bile acid homeostasis.

• GW4064: Non-Steroidal FXR Agonist Transforming Metabolic Res

  2026-06-17

  GW4064 is a highly selective, non-steroidal FXR agonist that enables rigorous investigation of bile acid metabolism, triglyceride regulation, and the FXR/TLR4/ferroptosis axis. This article delivers advanced experimental workflows, troubleshooting strategies, and novel insights from recent landmark studies—positioning GW4064 from APExBIO as the gold standard for metabolic and fibrosis research.

• ARID1A Loss Drives Osimertinib Resistance via PTEN/Akt Axis

  2026-06-16

  This study reveals that loss of ARID1A, a key chromatin remodeler, promotes resistance to the EGFR inhibitor osimertinib in lung adenocarcinoma by suppressing PTEN transcription and activating the Akt pathway. The findings highlight the ARID1A–PTEN–Akt axis as a critical determinant of drug sensitivity, with implications for overcoming resistance and guiding next-generation therapeutic strategies.

• CHIR-99021 (CT99021): A Benchmark GSK-3 Inhibitor for Plurip

  2026-06-16

  CHIR-99021 (CT99021) is a highly selective small molecule inhibitor of glycogen synthase kinase-3 (GSK-3) used extensively in stem cell research. It enables precise modulation of Wnt/β-catenin signaling, supporting embryonic stem cell pluripotency and controlled differentiation. Its potency and specificity make it a standard for in vitro and in vivo pathway studies.

• Biotin Azide: Precision Labeling for Lipid Signaling and Can

  2026-06-15

  Explore how Biotin Azide, a high-purity biotinylation reagent, is revolutionizing bio-orthogonal chemical labeling for advanced studies in lipid metabolism and Wnt/β-catenin signaling—key pathways in cancer. This thought-leadership article bridges mechanistic insight with strategic protocol guidance, referencing recent discoveries in cholesterol-Fzd5 signaling and demonstrating how APExBIO's Biotin-azide empowers translational researchers from interactomics to clinical innovation.

• Annexin V, human recombinant: Precision Tools for Quantitati

  2026-06-15

  Explore how Annexin V, a leading phosphatidylserine binding protein, enables rigorous, quantitative apoptosis analysis. This article unpacks structural innovations and advanced workflows, offering unique insights for cell death research.

• Applied Workflows for Eicosapentaenoic Acid in Cardiovascula

  2026-06-14

  Eicosapentaenoic Acid (EPA) advances cardiovascular and immunometabolic research with its precise modulation of membrane dynamics and lipid profiles. This article delivers actionable workflows, troubleshooting strategies, and cross-domain insights, empowering researchers to extract maximal value from APExBIO’s high-purity EPA omega-3 fatty acid.

• Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-TK

  2026-06-13

  This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly inhibits angiogenesis by blocking VEGFR2, PDGFRβ, and FGFR1 signaling. These findings highlight its superior efficacy in restricting endothelial cell migration and capillary tube formation, framing anlotinib as a valuable tool for cancer research and anti-angiogenic assay development.

• Superoxide Dismutase Activity Assay Kit: Assay Precision, Me

  2026-06-12

  Explore the Superoxide Dismutase Activity Assay Kit for advanced SOD activity quantification. This article uniquely examines assay specificity, practical protocol optimization, and insights from recent literature to guide oxidative stress research.

• EZH2 Controls Mesenchymal Gene Repression in Breast Cancer C

  2026-06-12

  Gallardo et al. reveal that EZH2, the catalytic subunit of PRC2, directly represses mesenchymal genes to maintain the epithelial phenotype in breast carcinoma cells. This study establishes a conserved mechanism for PRC2-mediated regulation of epithelial-mesenchymal plasticity, with significant implications for cancer epigenetics research and therapeutic targeting.

• CHIR-99021 (CT99021): Optimizing Stem Cell Differentiation W

  2026-06-11

  CHIR-99021 (CT99021) enables precision control of Wnt/β-catenin and TGF-β/Nodal signaling, streamlining pluripotency and directed differentiation in advanced stem cell and organoid models. This article translates the latest organoid engineering breakthroughs into actionable protocols and troubleshooting strategies for maximizing reproducibility and lineage specificity.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc

  2026-06-11

  Masitinib (AB1010) is a phenylaminothiazole-type tyrosine kinase inhibitor that facilitates selective inhibition of KIT, PDGFRα, and PDGFRβ in cancer, mastocytosis, and inflammatory disease research. It is best suited for DMSO-based workflows requiring targeted kinase inhibition and is not appropriate for applications necessitating broad-spectrum kinase inhibitors or aqueous/ethanol solubility.

• Foretinib (GSK1363089): Applied Workflows for Tumor Growth I

  2026-06-10

  Foretinib (GSK1363089) empowers researchers to dissect tumor growth, cell motility, and metastasis in robust in vitro and in vivo models. This guide translates mechanistic insights and reference-driven parameters into strategic workflows, with troubleshooting and protocol optimization for reproducible results.

• GW4064: Non-Steroidal FXR Agonist Workflows in Metabolic Res

  2026-06-10

  GW4064 stands out as a potent, selective non-steroidal FXR agonist for dissecting FXR/TLR4 and ferroptosis crosstalk in liver fibrosis and metabolic disease models. This guide details experimental workflows, troubleshooting, and recent innovations enabling rigorous use of GW4064 in advanced cellular and animal studies.

• Anlotinib Hydrochloride: Advanced Workflows for Angiogenesis

  2026-06-09

  Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, unlocks high-fidelity inhibition of angiogenesis for translational cancer research. This guide details experimental workflows, troubleshooting strategies, and applied insights, showing how to maximize robust, reproducible results with APExBIO’s benchmark compound.

14441 records 1/963 page Next 12345 下5页 Last page